NeurologyLive Friday 5 — October 22, 2021

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 22, 2021.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: The Need for Palliative Care in Parkinson Disease: Indu Subramanian, MD

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers spoke to the importance of utilizing palliative care principles in the regular care of Parkinson disease, and pointed clinicians to the newly formed International Neuropalliative Care Society, which will be virtually holding its first annual conference November 4-6, 2021.

2: Podcast: Episode 49: Altering the View of MS With a Topographical Model

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Stephen Krieger, MD, professor of neurology, Icahn School of Medicine, and staff neurologist, Corinne Goldsmith Dickinson Center for MS, Mount Sinai, who discussed the development of his topographical model of MS and how it has been leveraged to this point.

3: NeuroVoices: Jeffery Cohen, MD, on Alternative Methods to Tackling Progressive MS

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the realistic outlook of mesenchymal stem cells and other approaches to progressive MS, and stressed the need to continue to try to break through the barriers of progressive MS, as it remains the most challenging form of MS to treat.

4: CURE Connections: Treatment Advances in NMOSD

Episode 11 of the NeurologyLive CURE Connections series, "Managing Neuromyelitis Optica Spectrum Disorders (NMOSD)," features Brian G. Weinshenker, MD, offering his envisionment of the future management of neuromyelitis optica spectrum disorders based on his involvement in research programs and treatment advances occurring in neurology.

5: Aducanumab’s Clinical Use in Alzheimer Disease Appears Limited Post-Approval

Despite projections that aducanumab (Aduhelm; Biogen) would be widely adopted in clinical practice after its June 2021 approval, financial reports suggest a different story. Jessica Zwerling, MD, MS, offered her perspective on its clinical application thus far.

—————————————————
Introducing: Giants of Multiple Sclerosis™

Recognize and celebrate the individuals who have achieved landmark successes within multiple sclerosis! Giants of Multiple Sclerosis™ is a premier neuroscience award that celebrates pioneers, innovators, and future generations of leaders who have been selected by their peers for their remarkable achievements in Multiple Sclerosis.

More information will be announced at a welcome reception during the 2021 Consortium of MS Centers Annual Meeting.

Click here to RSVP to Attend

Aren't registered for the 2021 CMSC Annual Meeting? Register now.